Updated 16:30 IST, 22st April 2003
Molecular Connections ties up with Triesta to develop biomarkers
EPP News Bureau – New Delhi
The Bangalore-based bio-informatics company Molecular Connections and Triesta Sciences, a clinical genomics company, based in Menlo Park, CA, have entered into a strategic alliance in the area of biomarker discovery and validation.
As a part of the alliance, Molecular Connections will provide its advanced information extraction, informatics and pathway analysis expertise for Triesta Sciences’ biomarker discovery program. “We are very pleased to be working with Triesta in their efforts to identify novel biomarkers in clinical samples” said Jignesh Bhate, founder and director of Molecular Connections in a press communique.
Molecular Connections’ powerful information extraction technologies and analysis tools help biopharmaceutical scientists to efficiently navigate, integrate and analyze data from various unstructured and structured sources.
Molecular Connections, headquartered in Bangalore, is a joint venture between Idea2solutions an incubator promoted by the founders of the Dr Reddy’s group and Laboratories for Information Technology, Singapore, a national research institute for advanced technologies.
Molecular Connections’ initial focus is to build state-of-the-art products and provide world-class services to enhance efficiency, reduce the discovery cycle time and minimize the resources spent by drug discovery companies. The company utilizes proprietary Natural Language Processing based tools to extract, curate and annotate key biomedical information from literature and databases.
Molecular Connections is currently applying its technology to extract bio-molecular interactions from literature, particularly protein-protein, gene-drug, DNA-protein interactions and has developed the most comprehensive database of protein-protein interactions from literature. It has offices in Gaithersburg, Maryland and Bangalore, India.
Triesta BioSciences is a privately owned clinical genomics company based in Menlo Park, CA and Bangalore, India. Triesta undertakes clinical and molecular evaluation and validation of new targets and markers in partnership with international diagnostics and pharmaceutical companies. Triesta has disease programmes in the areas of oncology, infectious diseases, gastrointestinal disorders and renal disease.